Williamstown, MA -- (SBWIRE) -- 11/30/2011 -- GlobalData, the industry analysis specialist, has released its new report, "Huntington's Disease (HD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Huntington's disease market. The report identifies the key trends shaping and driving the global Huntington's disease market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Huntington's disease sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
View Full Report Details and Table of Contents
GlobalData estimates that the global Huntington's disease therapeutics market was valued at $246m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 13.4% over the next eight years, to reach $676m by 2018. This high value growth is primarily attributed to high cost of therapy of Xenazine (tetrabenazine) in the US and Huntexil (pridopidine) which is expected to launch in 2014. The current Huntington's disease therapeutics market is governed by off-label use of antipsychotics (risperidone, olanzapine), antidepressants (paroxetine, citalopram) and antiepileptics (valproic acid, carbamazepine) which are providing symptomatic relief.
Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).
The report provides information on the key drivers and challenges of the Huntington's disease market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Huntington's disease market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as antioxidant, Neuroprotective, Dopidine, mGlu 5 Receptor antagonist, T-cells activator, Sirt 1(sirtuin) Inhibitor, Oligomer formation inhibitor, monoamine oxidases A and B inhibitor, N-methyl-D-aspartate (NMDA) receptors antagonist, Neurotrophic factor production accelerator, SIRT2 inhibitor, amyloid peptides (AaY) inhibitor, stem cell therapy, gene therapy.
- Analysis of the current and future competition in the global Huntington's disease market. Key market players covered are Valeant International, Neurosearch and Avicena Group.
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Atherosclerosis or Coronary Artery Disease Therapeutics (CAD) - Pipeline Assessment and Market Forecasts to 2018
- Chronic Kidney Disease (CKD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Crohn's Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Gastroesophageal Reflux Disease (GERD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Ulcerative Colitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Major Depressive Disorder (MDD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Idiopathic Pulmonary Fibrosis (IPF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Muscular Dystrophy (MD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018